HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Acrivon Therapeutics, maintaining a price target of $22. Analyst Emily Bodnar continues to support the company's potential.
September 16, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Acrivon Therapeutics, maintaining a price target of $22. Analyst Emily Bodnar continues to support the company's potential.
The reiteration of a Buy rating and maintenance of a $22 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in ACRV's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100